ClinicalTrials.gg
Not yet recruitingNCT07935538Updated Nov 13, 2026

Effect of Hand Fist-Clenching Exercise Versus Topical Aloe Vera Gel in the Prevention of Peripheral Intravenous Catheter-Related Phlebitis Among Adult Patients

An interventional study of Hand fist -clenching exercise and topical Aloe vera gel in Peripheral Intravenous Catheter-related Phlebitis, Hand Fist -Clenching and Prevention, sponsored by Fatima Hussein Ali Hamad. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Fatima Hussein Ali Hamad · Not applicable, Interventional, and Prevention

How we know

Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study aims to evaluate and compare the effectiveness of hand fist-clenching exercises versus topical Aloe Vera gel in preventing peripheral intravenous catheter (PIVC)-related phlebitis among adult patients. Phlebitis is a common complication associated with IV therapy. The study will assess adult patients admitted to the internal medicine wards to determine which preventive intervention is more effective in reducing the incidence of phlebitis."

02

Conditions studied

  • Peripheral Intravenous Catheter-related Phlebitis
  • Hand Fist -Clenching
  • Prevention
  • Adult Patient
  • Topical Aloe Vera Gel

Browse trials for

03

In context

Phlebitis

47 studies on the registry are indexed under Phlebitis; 10 are open to participants now.

This study's planned enrollment of 60 is below the median of 123 across 39 interventional studies indexed under Phlebitis.

Browse Phlebitis studies →

Lead sponsor

This is the only study on the registry with Fatima Hussein Ali Hamad as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Are adults aged 18 years and above.
  2. Require peripheral intravenous catheterization.
  3. Have no signs of phlebitis at the selected IV insertion site before catheterization.
  4. Have intact skin at the selected IV insertion site.
  5. Are conscious and able to cooperate with the study procedures.
  6. Are able to perform the hand fist-clenching exercise.
  7. Agree to participate in the study.

    -

Exclusion Criteria:Participants with:

  1. Patients with existing phlebitis at the selected IV insertion site.
  2. Patients with skin disorders or lesions at the selected IV insertion site.
  3. Patients with acute or chronic infections.
  4. Patients with peripheral vascular disease or vascular abnormalities affecting the selected limb.
  5. Patients with conditions that prevent or limit performing the hand fist-clenching exercise.
  6. Patients who are unconscious, confused, or unable to cooperate with the study procedures.
  7. Patients with a known allergy or to Aloe Vera or any component of the topical gel.
  8. Patients requiring immediate removal of the peripheral intravenous catheter before completion of the observation period.

    -

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    hand fist -clenching exercise

    Behavioral: Hand fist -clenching exercise

  • Experimental
    topical aloe vera gel

    Other: topical Aloe vera gel

  • No intervention
    control group

Interventions

  • BehavioralHand fist -clenching exercise

    Initiation and Patient Education: Hand fist-clenching exercise will be initiated immediately after insertion of the peripheral intravenous catheter (PIVC). The exercise will be taught to the patient by the researcher, and the procedure will be demonstrated to ensure that the patient understands how to perform it. Exercise Procedure: The patient will perform the exercise by making a fist with the hand in which the PIVC is inserted. The fist will be maintained for 30 seconds to 1 minute for each repetition. Frequency and Duration: The exercise will be performed approximately 20 times during each session, with each session lasting 5-10 minutes. The exercise will be performed twice daily. Supervision: The patient's performance of the exercise will be conducted under the supervision of the researcher.

  • Othertopical Aloe vera gel

    Catheter Insertion Site Preparation and Insertion * Within the aloe vera gel intervention group, the intended catheterinsertion site underwent initial disinfection using a 70% ethyl alcoholsolution. * Subsequent to the complete evaporation of the alcohol, the nurseintroduced the angiocatheter , and its position was stabilized throughthe application of an angiocatheter securement adhesive. * Finally, 0.5 cc of aloe vera gel was topically applied to the superioraspect of the aforementioned adhesive.. 2\. Follow-up and Assessment * The insertion sites were monitored every 12 hours for a period following catheter placement to detect any indications of phlebitis,which were documented dichotomously (Yes/No). 3\. Standardization of Catheter Insertion * The angiocatheter insertions were executed by a registered nurse with a decade of professional experience within the internal medicine department.

06

What researchers measure

Primary outcomes

  1. incidence of peripheral intravenous catheter -related Phlebitis

    The incidence of phlebitis will be assessed using the Visual Infusion Phlebitis (VIP) scale. The VIP scale ranges from 0 (no signs of phlebitis) to 5 (advanced stage of thrombophlebitis). A score of 1 or greater indicates the occurrence of phlebitis

    Time frame: assessed twice daily for 48 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Tosun B, Gungor S, Agkale E, Andi S. Evaluation of the effect of proximal massage and palm fisting in reducing the risk of peripheral venous catheter-related phlebitis: randomized control study. Eur J Cardiovasc Nurs. 2024 Sep 5;23(6):644-651. doi: 10.1093/eurjcn/zvae024. PubMed 38366675 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.

Of 21 non-industry interventional studies with no phase under Phlebitis, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 3 months is below that.

Counting every sponsor, half of 21 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 13, 2026
StartEst.
Nov 22, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07935538
Lead sponsor
Fatima Hussein Ali Hamad
Responsible party
Fatima Hussein Ali Hamad (master student, Karbala University) — Sponsor-investigator
First posted
Nov 13, 2026
Start date
Nov 22, 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Fatima H Ali
Contact
fatima.h.ali@s.uokerbala.edu.iq
+9647711323620

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion